# Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Study · id `cardio:ct-nct04196231` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04196231](<https://clinicaltrials.gov/study/NCT04196231>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04196231

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 258 participants.

## Technical summary

Registry record NCT04196231. Randomized; no masking; primary purpose treatment. Start 2019-11-27 (actual); primary completion 2020-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 258 participants (enrolled count; ClinicalTrials.gov record NCT04196231, source copy `cardio:ctgov-nct04196231-2020-10-22`, retrieved 2026-10-26)
- Started: 2019-11-27 (actual) (ClinicalTrials.gov record NCT04196231, source copy `cardio:ctgov-nct04196231-2020-10-22`, retrieved 2026-10-26)
- Primary completion: 2020-09-30 (actual) (ClinicalTrials.gov record NCT04196231, source copy `cardio:ctgov-nct04196231-2020-10-22`, retrieved 2026-10-26)
- Completion: 2020-10-20 (actual) (ClinicalTrials.gov record NCT04196231, source copy `cardio:ctgov-nct04196231-2020-10-22`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT04196231, source copy `cardio:ctgov-nct04196231-2020-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04196231-2020-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
- Acronym: BEYOND
- Condition: Type 2 Diabetes
- Intervention (Drug): IDegLira
- Intervention (Drug): IGlarLixi
- Intervention (Drug): Insulin/Canaglifozin
- Intervention (Drug): Insulin/Dapaglifozin
- Intervention (Drug): Insulin/Empaglifozin
- Intervention (Drug): Basal Bolus
- Lead sponsor: University of Campania Luigi Vanvitelli
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Campania Luigi Vanvitelli (`cardio:org-university-of-campania-luigi-vanvitelli`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial (`cardio:pubmed-33883195`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes (`cardio:pubmed-37787888`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0c20d2c2fa92d6870b838e92ac0d8afc0bd49a1d8aabd58a741d61e025914204
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
